Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (17207)	3/11/1998 1:38:00 PM
From: Henry Niman	Respond to of 32384

Maybe Jesse has been reading the LGND thread again :-) "There are studies to suggest that Evista can prevent breast cancer in patients over three years, data that are due to be highlighted at the American Society of Clinical Oncology meeting in May. Those numbers "will be so striking they will generate a tremendous amount of media interest, which in turn will spur tremendous consumer interest," says Walsh." This is VERY good news for LGND. As I said, animal data has already shown the Panretin can synergize with Evista to prevent breast cancer in rats. Showing that Evista can also do so in humans, coupled with the research agreement with LGND targeting combination therapy using a Rexinoid (Targretin) and SERM (Evista), should open some eyes. ASCO is in May and LGND will be there in force! Michael Sporn's published paper on rat breast cancer chemoprevention study using Evista (Raloxifene) combined with Panretin (9-cis retinoic acid): J Natl Cancer Inst 1996 Jan 17;88(2):123-125 Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB Laboratory of Chemoprevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. PMID: 8537973, UI: 96133632